Published in AIDS Weekly, September 21st, 1998
Companies that bring potent new antiretroviral drugs to market deserve a reward in addition to compensation for development costs. But this reward cannot come at the cost of collapsing the fragile system that makes it possible for many people with HIV disease to stay alive.
Two new AIDS drugs are on the verge of entering the market: DuPont Pharma's efavirenz and Glaxo's abacavir. These drugs will mean life or death to many patients who already have failed currently available treatments. They will greatly strengthen the AIDS drug armamentarium.
How ironic it would be if overpricing of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.